Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) have been given an average recommendation of “Moderate Buy” by the nine research firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $44.11.

Several equities research analysts recently weighed in on the company. Raymond James restated an “outperform” rating and set a $40.00 target price on shares of Harmony Biosciences in a research note on Thursday. Needham & Company LLC restated a “buy” rating and set a $52.00 price objective on shares of Harmony Biosciences in a research report on Wednesday, October 2nd. UBS Group initiated coverage on shares of Harmony Biosciences in a research report on Tuesday, September 10th. They issued a “buy” rating and a $56.00 target price on the stock. Citigroup began coverage on Harmony Biosciences in a report on Friday, June 21st. They issued a “buy” rating and a $48.00 target price for the company. Finally, Mizuho upped their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday.

Harmony Biosciences Trading Up 0.1 %

HRMY opened at $34.83 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.13 and a quick ratio of 3.09. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of 15.08, a PEG ratio of 0.67 and a beta of 0.73. The business has a fifty day moving average price of $36.19 and a 200 day moving average price of $32.76. Harmony Biosciences has a 12 month low of $18.61 and a 12 month high of $40.60.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.24. The company had revenue of $172.80 million for the quarter, compared to the consensus estimate of $172.53 million. Harmony Biosciences had a net margin of 17.53% and a return on equity of 22.97%. The company’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.56 EPS. Sell-side analysts expect that Harmony Biosciences will post 2.19 earnings per share for the current fiscal year.

Institutional Trading of Harmony Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. nVerses Capital LLC purchased a new stake in shares of Harmony Biosciences during the 2nd quarter worth $36,000. CWM LLC lifted its stake in shares of Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after purchasing an additional 775 shares during the period. Quarry LP acquired a new position in Harmony Biosciences during the second quarter worth about $62,000. Headlands Technologies LLC increased its holdings in Harmony Biosciences by 1,608.1% in the second quarter. Headlands Technologies LLC now owns 2,545 shares of the company’s stock valued at $77,000 after buying an additional 2,396 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Harmony Biosciences during the 2nd quarter valued at approximately $138,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.